At the kidney level, SGLT2 inhibitors attenuate intraglomerular hypertension and single nephron hyperfiltration by activating tubuloglomerular feedback [11, 12], a mechanism likely linked with albuminuria lowering in the setting of diabetes [13, 14]. Here, SLC5A2 is linked to hypertensive disorder.